Drug Profile
Research programme: pain therapeutics - Endo/Harvard University
Latest Information Update: 26 Mar 2012
Price :
$50
*
At a glance
- Originator Harvard University; Massachusetts General Hospital
- Developer Endo Pharmaceuticals; Harvard University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 26 Mar 2012 No development reported for Pain in USA (unspecified route)
- 10 Feb 2009 Early research in Pain in USA (unspecified route)